

# Kelly E Seaton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3357711/publications.pdf>

Version: 2024-02-01

47  
papers

2,642  
citations

304743

22  
h-index

214800

47  
g-index

49  
all docs

49  
docs citations

49  
times ranked

4075  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. <i>Science Translational Medicine</i> , 2014, 6, 228ra39.	12.4	412
2	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. <i>Nature</i> , 2018, 561, 479-484.	27.8	392
3	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. <i>Nature Medicine</i> , 2018, 24, 1701-1707.	30.7	195
4	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	12.6	191
5	T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. <i>JCI Insight</i> , 2017, 2, .	5.0	164
6	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014, 505, 502-508.	27.8	140
7	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , 2017, 14, e1002435.	8.4	104
8	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	8.2	95
9	Multiple HIV-1-specific IgG3 responses decline during acute HIV-1. <i>Aids</i> , 2011, 25, 2089-2097.	2.2	79
10	Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles. <i>Journal of Infectious Diseases</i> , 2014, 210, 99-110.	4.0	73
11	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. <i>PLoS ONE</i> , 2019, 14, e0219142.	2.5	58
12	Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. <i>Journal of Virology</i> , 2015, 89, 9952-9961.	3.4	55
13	A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa. <i>EClinicalMedicine</i> , 2020, 21, 100313.	7.1	52
14	Vi-specific serological correlates of protection for typhoid fever. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	45
15	Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. <i>MAbs</i> , 2017, 9, 792-800.	5.2	43
16	IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model. <i>Frontiers in Immunology</i> , 2019, 10, 2582.	4.8	40
17	HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities. <i>PLoS ONE</i> , 2014, 9, e101863.	2.5	36
18	Neurotensin receptor-1 inducible palmitoylation is required for efficient receptor-mediated mitogenic-signaling within structured membrane microdomains. <i>Cancer Biology and Therapy</i> , 2011, 12, 427-435.	3.4	32

#	ARTICLE	IF	CITATIONS
19	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 1280-1288.	4.0	32
20	Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with <i>Plasmodium falciparum</i> Circumsporozoite Protein Antigens. <i>Journal of Immunology</i> , 2018, 201, 1315-1326.	0.8	30
21	Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. <i>PLoS ONE</i> , 2017, 12, e0179597.	2.5	29
22	HIV-1-negative female sex workers sustain high cervical IFN $\gamma$ , low immune activation, and low expression of HIV-1-required host genes. <i>Mucosal Immunology</i> , 2016, 9, 1027-1038.	6.0	28
23	Innate Activation of MDC and NK Cells in High-Risk HIV-1 Exposed Seronegative IV-Drug Users Who Share Needles When Compared With Low-Risk Nonsharing IV-Drug User Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 264-273.	2.1	23
24	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. <i>Journal of Virology</i> , 2017, 91, .	3.4	23
25	Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel. <i>Mucosal Immunology</i> , 2016, 9, 821-833.	6.0	22
26	HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. <i>Journal of Virology</i> , 2017, 91, .	3.4	20
27	Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1. <i>Journal of Virology</i> , 2019, 93, .	3.4	20
28	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. <i>Nature Immunology</i> , 2021, 22, 1294-1305.	14.5	20
29	N-Myristoyltransferase isozymes exhibit differential specificity for human immunodeficiency virus type 1 Gag and Nef. <i>Journal of General Virology</i> , 2008, 89, 288-296.	2.9	19
30	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2116-2127.	3.3	17
31	Rectal tissue and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	17
32	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803.	2.5	16
33	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. <i>Clinical Infectious Diseases</i> , 2020, 72, 50-60.	5.8	15
34	SIMON: Open-Source Knowledge Discovery Platform. <i>Patterns</i> , 2021, 2, 100178.	5.9	15
35	Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. <i>Vaccine</i> , 2016, 34, 5344-5351.	3.8	11
36	Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection. <i>Npj Vaccines</i> , 2021, 6, 110.	6.0	11

#	ARTICLE	IF	CITATIONS
37	Computational analysis of antibody dynamics identifies recent HIV-1 infection. JCI Insight, 2017, 2, .	5.0	11
38	Analysis of the HIV Vaccine Trials Network 702 Phase 2bâ€³ HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. Journal of Infectious Diseases, 2022, 226, 246-257.	4.0	11
39	Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Scientific Reports, 2020, 10, 13031.	3.3	10
40	Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity. Journal of Pharmaceutical Sciences, 2020, 109, 233-246.	3.3	9
41	Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials. Frontiers in Big Data, 2021, 4, 672460.	2.9	8
42	Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. Npj Vaccines, 2021, 6, 56.	6.0	7
43	Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS. Frontiers in Immunology, 2021, 12, 709994.	4.8	4
44	Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 434-439.	2.1	3
45	Persistence of vaccine-elicited immune response up to 14Âyears post-HIV gp120-NefTat/AS01B vaccination. Vaccine, 2020, 38, 1678-1689.	3.8	2
46	Methods for comparing durability of immune responses between vaccine regimens in early-phase trials. Statistical Methods in Medical Research, 2020, 29, 78-93.	1.5	1
47	AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. Vaccine, 2021, 39, 4641-4650.	3.8	1